ReviewJournal of molecular medicine (Berlin, Germany)2013
The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review.
Review in Journal of molecular medicine (Berlin, Germany), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Interleukin-6-174G>C gene promoter polymorphism and prognosis in patients with cancer.Oncotarget · 2017Pooled it
- Trial
- Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.Gynecologic oncology · 2020Trial
- IL-6/IL-6R-Mediated Mechanisms in Lung Cancer: From Pathogenesis to Potential Therapeutic Targets.Immunology · 2026Review
- Review
- Humanized Antibodies Targeting Ectodomains of IL-6R and GP130 Suppress IL-6/STAT3 Signalling and Tumour Growth in Breast Cancer Models.Journal of cellular and molecular medicine · 2026Article
- Assessment of Interleukin-6 (IL-6) and Cotinine Levels in the Saliva of Patients with Precancerous Lesions and Oral Mucosa Cancer.Journal of clinical medicine · 2026Article
- Development of a Genetically Modified Lactococcus lactis Strain that Produces a Single-Chain Variable Fragment Targeting Interleukin-6 Receptor α to Suppress Serum Amyloid A.Current microbiology · 2025Article
- Transcriptome analysis of ovarian cancer uncovers association between tumor-related inflammation/immunity and patient outcome.Frontiers in pharmacology · 2025Article
- IL-6 is a prognostic biomarker in patients with advanced esophageal squamous cell carcinoma received with PD-1 inhibitors.Frontiers in immunology · 2025Article
- IL-6 regulates epithelial ovarian cancer EMT, invasion, and metastasis by modulating Let-7c and miR-200c through the STAT3/HIF-1α pathway.Medical oncology (Northwood, London, England) · 2024Article
- Integrated Bioluminescent Immunoassays for High-Throughput Sampling and Continuous Monitoring of Cytokines.Analytical chemistry · 2023Article
- Cancer and Covid-19: Collectively catastrophic.Cytokine & growth factor reviews · 2022Review
- Cachexia as Evidence of the Mechanisms of Resistance and Tolerance during the Evolution of Cancer Disease.International journal of molecular sciences · 2021Review
- COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?Journal of ovarian research · 2021Review
- Women who develop ovarian cancer show an increase in serum calcium and a decrease in serum albumin. A longitudinal study in the Janus Serum Bank Cohort.Gynecologic oncology · 2020Article
- Blocking inflammation to improve immunotherapy of advanced cancer.Immunology · 2020Review
- GP130 Cytokines in Breast Cancer and Bone.Cancers · 2020Review
- IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells.OncoTargets and therapy · 2020Article
- Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing number of studies emphasize the role of inflammation and metabolic changes in the induction of cancer-related symptoms, which can affect cancer evolution and prognosis. These changes result from the interactions between the tumor and the host. To date, however, markers of this peculiar condition, which can help clinicians to manage patients better, have still not been identified with certainty. Epithelial ovarian cancer (EOC) appears to be particularly appropriate to study these interactions because of its biological characteristics, its peculiar evolution, and the relevant scientific evidence available. Immunosuppression, anemia, depression, and weight loss affect the evolution of EOC and appear to be directly related to the immune-metabolic changes. In light of the aforementioned evidence, our review will focus on interleukin-6 (IL-6) and its role as potential marker of the patients' immune-metabolic status, to better monitor disease outcome and identify the most appropriate therapeutic strategy in EOC. Furthermore, leptin will be discussed as a sensor of the changes of energy metabolism induced by IL-6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.